In the case of pathological hypercoagulative conditions such as thrombosis and embolism, 4-hydroxycoumarin based oral anticoagulants, including warfarin as a well-known example, are administered to block the enzymatic function of VKORC1, effectively diminishing turnover of the vitamin K cycle.